Wall Street brokerages expect Theravance Biopharma Inc (NASDAQ:TBPH) to post earnings per share of ($1.18) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Theravance Biopharma’s earnings, with the lowest EPS estimate coming in at ($1.26) and the highest estimate coming in at ($1.02). Theravance Biopharma posted earnings per share of ($1.27) in the same quarter last year, which would suggest a positive year over year growth rate of 7.1%. The company is scheduled to report its next quarterly earnings report on Tuesday, November 6th.
According to Zacks, analysts expect that Theravance Biopharma will report full year earnings of ($4.41) per share for the current financial year, with EPS estimates ranging from ($4.70) to ($4.22). For the next year, analysts anticipate that the firm will report earnings of ($4.29) per share, with EPS estimates ranging from ($5.09) to ($3.72). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.20) by $0.44. Theravance Biopharma had a negative return on equity of 261.70% and a negative net margin of 640.07%. The company had revenue of $23.48 million during the quarter, compared to the consensus estimate of $9.97 million.
Shares of NASDAQ TBPH traded up $0.10 on Friday, hitting $29.94. The company had a trading volume of 146,318 shares, compared to its average volume of 235,388. Theravance Biopharma has a 12-month low of $21.27 and a 12-month high of $35.48. The company has a debt-to-equity ratio of 6.52, a current ratio of 4.14 and a quick ratio of 3.95. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -5.49 and a beta of 1.88.
In related news, SVP Philip D. Worboys sold 6,393 shares of the stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $28.50, for a total value of $182,200.50. Following the completion of the transaction, the senior vice president now owns 166,753 shares of the company’s stock, valued at $4,752,460.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Bradford J. Shafer sold 31,300 shares of the stock in a transaction dated Wednesday, August 8th. The shares were sold at an average price of $27.94, for a total value of $874,522.00. Following the completion of the transaction, the executive vice president now directly owns 127,606 shares of the company’s stock, valued at approximately $3,565,311.64. The disclosure for this sale can be found here. Insiders sold 88,555 shares of company stock valued at $2,425,865 in the last three months. 6.90% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Rhumbline Advisers boosted its holdings in Theravance Biopharma by 4.6% in the second quarter. Rhumbline Advisers now owns 39,781 shares of the biopharmaceutical company’s stock valued at $902,000 after purchasing an additional 1,757 shares during the last quarter. UBS Group AG boosted its holdings in Theravance Biopharma by 88.4% in the first quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 2,117 shares during the last quarter. Royal Bank of Canada boosted its holdings in Theravance Biopharma by 22.3% in the first quarter. Royal Bank of Canada now owns 16,664 shares of the biopharmaceutical company’s stock valued at $404,000 after purchasing an additional 3,042 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in Theravance Biopharma by 12.2% in the second quarter. State Board of Administration of Florida Retirement System now owns 28,578 shares of the biopharmaceutical company’s stock valued at $648,000 after purchasing an additional 3,100 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in Theravance Biopharma by 5.3% in the first quarter. Swiss National Bank now owns 75,142 shares of the biopharmaceutical company’s stock valued at $1,822,000 after purchasing an additional 3,800 shares during the last quarter. 85.80% of the stock is owned by hedge funds and other institutional investors.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.